Swedbank AB Buys 10,326 Shares of Natera, Inc. (NASDAQ:NTRA)

Swedbank AB lifted its position in Natera, Inc. (NASDAQ:NTRA) by 51.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,326 shares of the medical research company’s stock after acquiring an additional 10,326 shares during the period. Swedbank AB’s holdings in Natera were worth $4,801,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of NTRA. Chartwell Investment Partners LLC raised its holdings in Natera by 37.9% in the third quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after purchasing an additional 11,362 shares during the period. Cerity Partners LLC raised its stake in Natera by 27.0% during the 3rd quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock worth $10,936,000 after buying an additional 18,316 shares during the period. Wilmington Savings Fund Society FSB bought a new position in Natera during the third quarter worth about $385,000. Everence Capital Management Inc. acquired a new position in Natera in the fourth quarter valued at about $573,000. Finally, First Turn Management LLC bought a new stake in shares of Natera in the third quarter worth about $19,760,000. Institutional investors own 99.90% of the company’s stock.

Insider Buying and Selling

In other news, Director Rowan E. Chapman sold 1,767 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $170.24, for a total transaction of $300,814.08. Following the completion of the sale, the director now owns 6,202 shares in the company, valued at approximately $1,055,828.48. This trade represents a 22.17 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Michael Burkes Brophy sold 1,886 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $176.60, for a total transaction of $333,067.60. Following the completion of the transaction, the chief financial officer now owns 101,811 shares in the company, valued at approximately $17,979,822.60. This trade represents a 1.82 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 263,894 shares of company stock worth $43,801,978. Company insiders own 7.60% of the company’s stock.

Natera Price Performance

NASDAQ:NTRA opened at $176.92 on Friday. The stock has a market capitalization of $23.36 billion, a PE ratio of -100.52 and a beta of 1.65. Natera, Inc. has a 1-year low of $64.74 and a 1-year high of $183.00. The firm has a fifty day simple moving average of $166.89 and a 200 day simple moving average of $138.31. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company’s quarterly revenue was up 63.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.95) EPS. On average, research analysts expect that Natera, Inc. will post -1.56 EPS for the current fiscal year.

Analyst Ratings Changes

NTRA has been the topic of several recent analyst reports. Barclays started coverage on Natera in a report on Thursday, January 23rd. They set an “overweight” rating and a $200.00 price objective on the stock. Piper Sandler upped their price target on shares of Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, November 18th. Leerink Partners raised their price objective on shares of Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Guggenheim upped their target price on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. Finally, Craig Hallum lifted their price target on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $165.88.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.